Corcept Therapeutics

Latest news

• After a $1.13M September sale, Corcept (CORT) officer proposes another share sale. (opens in a new tab)

  Stock Titan · Oct 1, 2026

• Corcept Therapeutics options: a long strangle signals volatility bet ahead of 2027 (opens in a new tab)

  Investing.com · Sep 29, 2026

• Corcept Therapeutics stock carries a raised 2026 outlook (opens in a new tab)

  AD HOC NEWS · Sep 29, 2026

• Corcept Therapeutics (CORT) business chief gifts shares; two custodial accounts acquire 5,000 each (opens in a new tab)

  Stock Titan · Sep 28, 2026

• Corcept Therapeutics’ oncology president sells $29,842 in stock (opens in a new tab)

  Investing.com · Sep 28, 2026

• Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com (opens in a new tab)

  Investing.com Canada · Sep 28, 2026

• Is Corcept Therapeutics (CORT) Undervalued After CHMP Backing For Relacorilant? (opens in a new tab)

  Simply Wall Street · Sep 27, 2026

• Strong Commercial Execution and Pipeline Opportunities Propel Corcept Therapeutics (CORT) (opens in a new tab)

  Yahoo Finance · Sep 25, 2026

• Corcept Therapeutics Soars on Europe Cancer Drug Nod (opens in a new tab)

  tipranks.com · Sep 24, 2026

• CORT Looks 59.9% Overvalued on GF Value™ (opens in a new tab)

  GuruFocus · Sep 23, 2026

• Corcept Names Justin Gunn President of Endocrinology as Sean Maduck Retires (opens in a new tab)

  citybiz.co · Sep 23, 2026

• Corcept Therapeutics Announces New Endocrinology Division President (opens in a new tab)

  tipranks.com · Sep 23, 2026

• Corcept Therapeutics' Sean Maduck to Resign as President of Corcept Endocrinology, to Serve as Consultant (opens in a new tab)

  TradingView · Sep 23, 2026

• Corcept names Justin Gunn to lead endocrinology division By Investing.com (opens in a new tab)

  Investing.com Canada · Sep 23, 2026

• Corcept Announces Planned Leadership Transition (opens in a new tab)

  Business Wire · Sep 23, 2026

• Corcept Stock Sinks Despite Drug Win Euphoria (opens in a new tab)

  tipranks.com · Sep 23, 2026

• Does EU Ovarian Cancer Backing Change The Bull Case For Corcept Therapeutics Stock? (opens in a new tab)

  Simply Wall Street · Sep 23, 2026

• Health Care Weekly: Corcept Seeks Dismissal of Off-Label Marketing Whistleblower Suit; Medicare ACCESS Program to Cover More Chronic Conditions; FDA Launches Accelerated Investigational Drug Review Program; Agencies Announce Fresh Steps to C (opens in a new tab)

  The Capitol Forum · Sep 23, 2026

• Corcept Therapeutics (CORT) CHMP Backing Keeps Undervalued Narrative In Focus (opens in a new tab)

  Yahoo Finance · Sep 22, 2026

• Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle (opens in a new tab)

  Yahoo Finance · Sep 21, 2026

• Corcept Therapeutics stock falls after Q2 2026 earnings jump and analyst focus on risk-reward (opens in a new tab)

  AD HOC NEWS · Sep 20, 2026

• Corcept's Lifyorli recommended in EU for platinum-resistant ovarian cancer (opens in a new tab)

  app.dealroom.co · Sep 20, 2026

• Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Xenon (XENE) (opens in a new tab)

  The Globe and Mail · Sep 19, 2026

• Corcept Therapeutics president Vieira sells $29,842 of stock (opens in a new tab)

  Investing.com India · Sep 19, 2026

• Corcept Says EU Panel Backs Ovarian Cancer Drug Combination for Approval (opens in a new tab)

  Yahoo Finance · Sep 18, 2026

• Merck, Astra, Roche and Corcept among winners of EU drug recommendations this week (opens in a new tab)

  Seeking Alpha · Sep 18, 2026

• Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant) (opens in a new tab)

  Yahoo Finance · Sep 18, 2026

• Here’s How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 10 Years (opens in a new tab)

  Benzinga · Sep 17, 2026

• Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026? (opens in a new tab)

  Yahoo Finance · Sep 16, 2026

• Corcept Grows to Mid-Cap on Institutional Support (opens in a new tab)

  Yahoo Finance · Sep 16, 2026